Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines - A prospective multi-center study
异源与同源初免-加强免疫方案在灭活和腺病毒载体SARS-CoV-2疫苗中的免疫原性和安全性——一项前瞻性多中心研究
期刊:Heliyon
影响因子:3.6
doi:10.1016/j.heliyon.2023.e23246
Phuensan, Pawat; Sirimongkolkasem, Jarongkorn; Tantawichien, Terapong; Phannajit, Jeerath; Kerr, Stephen J; Hansasuta, Pokrath; Chantharit, Prawat; Wongsa, Adisorn; Fuengfoo, Pusit; Chittinandana, Anutra; Vareesangthip, Kriengsak; Chayakulkeeree, Methee; Jangsirikul, Sureeporn; Schmidt, Araya; Wanvimonsuk, Kanyika; Winichakoon, Poramed; Kajeekul, Rattagan; Prayoonwiwat, Wichai; Rerknimitr, Rungsun